Related Articles
ALK‑positive locally advanced lung cancer in a patient who achieved long‑term complete response with crizotinib: A case report
Successful oral desensitization with crizotinib after crizotinib‑induced hepatitis in an anaplastic lymphoma kinase‑rearranged non‑small‑cell lung cancer patient: A case report
Marked tumor response to crizotinib after 4 years of maintenance pemetrexed in a patient with anaplastic lymphoma kinase‑positive non‑small‑cell lung cancer
Clinical activity of crizotinib in lung adenocarcinoma harboring a <em>HLA_A</em>‑<em>ROS1</em> rearrangement: A case report
Response to alectinib after one year of discontinuation of crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer: A case report